DB-1303
Breakthrough HER2 ADC: DB-1303/BNT323 Outperforms Kadcyla in Positive Phase III Results in China
DB-1303 (BNT323) achieved a positive Phase III readout in HER2-positive breast cancer, reinforcing DualityBio’s ADC platform and BioNTech’s oncology expansion beyond immunotherapy. The trial shows potential for global commercialization, including a planned China BLA filing.